EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Pregabalin for Neuropathic Pain and Itch in Recessive Dystrophic Epidermolysis Bullosa

Margarita Calvo, Macarena Tejos-Bravo, Alvaro Passi-Solar, Fernanda Espinoza, Ignacia Fuentes, Irene Lara-Corrales, Elena Pope

JAMA Dermatology · 01.12.2024 · 160 (12) · 1314

DOI: 10.1001/jamadermatol.2024.3767 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Dermatology, erschienen am 01.12.2024. Verfasst von Margarita Calvo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Physiology Department, Biological Sciences Faculty, Pontificia Universidad Católica de Chile, Santiago, Chile. Hauptthemen laut MEDLINE: Pregabalin, Pruritus, Cross-Over Studies, Analgesics. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Patients with recessive dystrophic epidermolysis bullosa (RDEB) experience neuropathic pain and itch. There is a lack of evidence on any treatment for these symptoms in patients with RDEB.

Objectives

To test the efficacy of pregabalin in the treatment of neuropathic pain and itch in patients with RDEB. Design, Setting, and Participants A randomized, double-blinded, crossover trial of oral pregabalin (50-300 mg/d) vs placebo was conducted at 2 sites, Toronto (Canada) and Santiago (Chile) from January 1, 2019, to December 31, 2020. Patients eligible to participate were diagnosed with RDEB, aged 8 to 40 years, not pregnant or lactating (if female), and had evidence of probable neuropathic pain and itching defined as distal thermal sensory loss (confirmed by thermal roller), score of 4 or greater on the Douleur Neuropathique 4 questionnaire (DN4), and score greater than 4 on the 10-point visual analog scale [VAS]). Patients with a clinically important or poorly controlled medical or psychiatric condition or pregabalin intolerance or allergy were excluded. Of 41 patients screened, 3 were not eligible and 28 declined enrollment. Data analyses were performed in 2021 through 2023.

Intervention

Participants received both pregabalin and matched placebo (titrated to a maximum-tolerated dose of 300 mg/day) in a randomized sequence so that comparisons could be made within participants and between groups. Main Outcomes and Measures Difference in the mean pain and itch scores between pregabalin and placebo treatment (measured using VAS) before and after intervention.

Results

In all, 10 participants were randomized to 2 groups, 6 patients (mean [SD] age, 26.7 [8.1] years; 3 females [50%]) in group 1, and 4 patients (mean [SD] age, 26.5 [7.8] years, 2 females [50%]) in group 2. Group 1 received a sequence of pregabalin-placebo while group 2 received placebo-pregabalin. Pregabalin significantly reduced mean (SD) pain scores by 1.9 (1.5) points when controlling for sequence and treatment period vs baseline, while placebo had 0.1 (2.0) points of reduction. The effect of pregabalin was a mild but significant reduction in itch compared to baseline (mean [SD] points, 0.9 [2.2]), whereas the placebo produced no reduction (0.1 [2.5]). The mean pregabalin dose was generally well tolerated. Conclusions and Relevance The results of this randomized crossover trial indicate that pregabalin significantly reduced pain and itch scores from baseline compared to placebo in patients with RDEB. This feasibility study provided preliminary data on the efficacy of pregabalin in managing pain and itch in RDEB and gathered essential data to inform the design of a larger cohort trial. Trial Registration ClinicalTrials.gov Identifier: NCT03928093

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PregabalinPruritusCross-Over StudiesAnalgesicsNeuralgiaEpidermolysis Bullosa DystrophicaHumansFemaleMaleDouble-Blind MethodAdultAdolescentYoung AdultChildTreatment OutcomePain MeasurementAdministration, Oral

Substanzen

PregabalinAnalgesics

Autor:innen und Institutionen

  • Physiology Department, Biological Sciences Faculty, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Millennium Nucleus for the Study of Pain, Santiago, Chile.
  • Anesthesiology Division, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Public Health Department, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Center for Genetics and Genomics, Faculty of Medicine, Clínica Alemana, Universidad del Desarrollo, Santiago, Chile.
  • Fundación DEBRA Chile, Santiago, Chile.

Zitieren

APA

Calvo, M., Tejos-Bravo, M., Passi-Solar, A., Espinoza, F., Fuentes, I., Lara-Corrales, I., & Pope, E. (2024). Pregabalin for Neuropathic Pain and Itch in Recessive Dystrophic Epidermolysis Bullosa. JAMA Dermatology, 160(12), 1314. https://doi.org/10.1001/jamadermatol.2024.3767

Vancouver

Calvo M, Tejos-Bravo M, Passi-Solar A, Espinoza F, Fuentes I, Lara-Corrales I, et al. Pregabalin for Neuropathic Pain and Itch in Recessive Dystrophic Epidermolysis Bullosa. JAMA Dermatology. 2024;160(12):1314. doi:10.1001/jamadermatol.2024.3767

BibTeX
@article{Calvo2024,
  author = {Calvo, Margarita and Tejos-Bravo, Macarena and Passi-Solar, Alvaro and Espinoza, Fernanda and Fuentes, Ignacia and Lara-Corrales, Irene and Pope, Elena},
  title = {Pregabalin for Neuropathic Pain and Itch in Recessive Dystrophic Epidermolysis Bullosa},
  journal = {JAMA Dermatology},
  year = {2024},
  volume = {160},
  number = {12},
  pages = {1314},
  doi = {10.1001/jamadermatol.2024.3767}
}
Kostenlos starten →